SCHEMBL3577810

SCHEMBL3577810

COCCCN1C[C@@H](O)c2ccsc2S1(=O)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.47
CA4 P22748 2/20 0.47
LMNA P02545 2/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA13 Q8N1Q1 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
GAA P10253 3/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3586845 1.00 CA2 (0.47) CA2CA4LMNACA12CA1
SCHEMBL3585070 1.00 CA2 (0.47) CA2CA4LMNACA12CA1
SCHEMBL7508801 0.93 CA2 (0.39) CA2CA4LMNACA12CA1
SCHEMBL8950462 0.88 CA2 (0.37) CA2CA4LMNACA12CA1
SCHEMBL18651229 0.82 CA2 (0.45) CA2CA4LMNACA12CA1
SCHEMBL3583041 0.81 CA2 (0.63) CA2CA4LMNACA12CA1
SCHEMBL3583044 0.81 CA2 (0.63) CA2CA4LMNACA12CA1
SCHEMBL4703333 0.80 CA2 (0.42) CA2CA4LMNACA12CA1
SCHEMBL18651237 0.80 CA2 (0.42) CA2CA4LMNACA12CA1
SCHEMBL2631337 0.79 CA2 (0.53) CA2CA4LMNACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009977-A1 Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. USV LTD. (IN) 2010-01-14 US disclosed
US-20100009977-A1 Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. USV LTD. (IN) 2010-01-14 US disclosed
US-20100009977-A1 Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. USV LTD. (IN) 2010-01-14 US disclosed
EP-2079749-A2 IMPROVED PROCESS FOR THE PREPARATION OF (R)-(+)-4-(ETHYIAMINO)-3,4-DIHYDRO-2-(3- METHOXYPROPYL)-2H-THIENO[3,2-E]-L,2-THIAZINE-6-SULFONAMIDE-L,L-DIOXIDE USV LIMITED (IN) 2009-07-22 EP disclosed
WO-2008132114-A1 PROCESS FOR THE PREPARATION OF BRINZOLAMIDE AND INTERMEDIATES THEREOF DUKE CHEM, S. A. (ES) 2008-11-06 WO disclosed
EP-1985618-A1 Process for the preparation of brinzolamide and intermediates thereof Duke Chem, S. A. (ES) 2008-10-29 EP disclosed
WO-2008062463-A2 IMPROVED PROCESS FOR THE PREPARATION OF (R)-(+)-4-(ETHYIAMINO)-3,4-DIHYDRO-2-(3- METHOXYPROPYL)-2H-THIENO[3,2-E]-L,2-THIAZINE-6-SULFONAMIDE-L,L-DIOXIDE USV LIMITED (IN) 2008-05-29 WO disclosed
US-5470973-A Synthesis of sulfonamide intermediates ALCON LABORATORIES, INC. (US) 1995-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009977-A1 Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. SULT1E1, SULT1A1, SULT2A1 CA2 1631/4885CA4 709/4885LMNA 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.